Verrica Pharmaceuticals Inc. splits its revenue into 3 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Product at $5.1 million, 87% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
30
|
6
|
5
|
5
|
14
|
13
|
3
|
0
|
-2
|
| Product |
17
+160.9%
share 55.1%
|
5
+12.3%
share 86.9%
|
4
+25.4%
share 85.4%
|
4
+1081.6%
share 73.1%
|
4
+293.4%
share 25.1%
|
5
share 35.7%
|
3
share 99.5%
|
0
share 91.6%
|
-2
share 104.7%
|
| License And Collaboration Revenue |
14
+64.0%
share 44.9%
|
1
-90.6%
share 13.1%
|
1
+4211.8%
share 14.6%
|
1
+4624.1%
share 26.9%
|
11
+12682.1%
share 74.9%
|
8
share 64.3%
|
0
share 0.5%
|
0
share 8.4%
|
0
share -4.7%
|
| License And Collaboration Revenue Commercial Supply And Development |
—
|
—
|
1
+4017.6%
share 13.9%
|
1
share 27.5%
|
1
+600.0%
share 4.9%
|
—
|
0
share 0.5%
|
0
share 0.0%
|
0
share -5.6%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VRCA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- West Chester, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1660334
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.